Clinical trials of efficacy of praziquantel horse paste 9% against tapeworms and its safety in horses

The aim of this study with horses and a few ponies naturally infected with tapeworms was to confirm in clinical trials the efficacy and safety of a praziquantel horse paste 9%. The field trials were conducted in 1997 and 1998 in Canada, France, Germany and New Zealand. A secondary aim of the study in Canada was to determine if a 24 h post-treatment fecal sample provides the best estimate of the prevalence of tapeworms in horses when using a fecal examination technique. Fecal samples were taken from each of 1062 animals at least three times pre-treatment (PRT). In Canada, fecal samples were examined using the Cornell–Wisconsin centrifugal flotation technique, and in France, Germany and New Zealand using a centrifugation/flotation technique. In each trial, the animals were randomized into two treatment groups: praziquantel horse paste 9% at 1 mg/kg body weight (BW) and untreated. Fecal samples were taken from each animal nine times post-treatment and over a period of 5 weeks. In Canada, a fecal sample was taken also at 24 h after treatment. Personnel examining the samples were “blinded” to treatment groups. On the day of treatment, each treated animal was examined for adverse reactions to the paste 10 min after treatment and then hourly for 4 h. Thereafter, each animal was examined once daily for 5 weeks. In Canada, Germany and New Zealand, the only tapeworm egg found was Anoplocephala perfoliata. In France, A. perfoliata was the most common species and a few animals had A. magna and Paranoplocephala mamillana. The prevalence of A. perfoliata among animals sampled in Canada, France, Germany and New Zealand was 51.8, 34.4, 13.1 and 26.2%, respectively. A total of 248 animals were treated with the praziquantel paste and all except one accepted it readily. There were 292 animals completing the study, 219 treated and 73 untreated. In Canada, Germany and New Zealand, the efficacy of the praziquantel horse paste 9% against A. perfoliata was 100%. In France, the efficacy against A. perfoliata, A. magna and P. mamillana was 90.9, 100 and 100%, respectively. The best estimate of prevalence for A. perfoliata in a herd was derived from fecal samples taken 24 h after treatment. At 24 h, 22 of 23 treated horses were positive, whereas on any day pre-treatment fewer horses were positive. Adverse reactions observed were mild to moderate colic and in only two treated horses.